<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> (<z:chebi fb="0" ids="52717">Velcade</z:chebi>, formerly <z:chebi fb="0" ids="52717">PS-341</z:chebi>) is <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> with documented antitumor activity in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and other lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in patients with <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> refractory to or relapsing after prior therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m(2) <z:chebi fb="0" ids="52717">bortezomib</z:chebi> administered twice weekly for 4 weeks every 6 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Dose-limiting toxicity included <z:hpo ids='HP_0001278'>orthostatic hypotension</z:hpo> (n = 2), <z:hpo ids='HP_0002018'>nausea</z:hpo> (n = 2), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (n = 1), and fluid retention (n = 1), <z:hpo ids='HP_0000001'>all</z:hpo> at 1.5 mg/m(2) <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Proteasome inhibition was dose dependent and reached 68% at 1.5 mg/m(2) <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Incubation of blast cells with <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in vitro showed induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in three of five patients investigated </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that the maximum tolerated dose of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> is 1.25 mg/m(2), using a twice-weekly for 4 weeks every 6 weeks schedule </plain></SENT>
<SENT sid="8" pm="."><plain>The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, probably in combination with other agents </plain></SENT>
</text></document>